KMT2A and acute myeloid leukemia: Mertk-loxp+/+Cre+ mice inoculated with MLL-ENL AML demonstrated extension of survival of all but one mouse, compared to a median survival of 35 days in Mertk-loxp-/-Cre-/- mice (p<0.001) (Figure 1F).